Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 841 entries
Sorted by: Best Match Show Resources per page
Affective Correlates of Psychosis in Parkinson's Disease.

Movement disorders clinical practice

Factor SA, Scullin MK, Freeman A, Bliwise DL, McDonald WM, Goldstein FC.
PMID: 28944257
Mov Disord Clin Pract. 2017 Mar-Apr;4(2):225-230. doi: 10.1002/mdc3.12381. Epub 2016 Jun 16.

OBJECTIVE: To examine the nature of the association between affective disorders and psychosis in Parkinson's disease (PD).BACKGROUND: In PD, psychosis and affective disorders are common and independently impact quality of life and mortality. Both depression and psychosis are correlated...

Cite
Factor SA, Scullin MK, Freeman A, et al. Affective Correlates of Psychosis in Parkinson's Disease. Mov Disord Clin Pract. 2016;4(2):225-230doi: 10.1002/mdc3.12381.
Factor, S. A., Scullin, M. K., Freeman, A., Bliwise, D. L., McDonald, W. M., & Goldstein, F. C. (2017). Affective Correlates of Psychosis in Parkinson's Disease. Movement disorders clinical practice, 4(2), 225-230. https://doi.org/10.1002/mdc3.12381
Factor, Stewart A, et al. "Affective Correlates of Psychosis in Parkinson's Disease." Movement disorders clinical practice vol. 4,2 (2017): 225-230. doi: https://doi.org/10.1002/mdc3.12381
Factor SA, Scullin MK, Freeman A, Bliwise DL, McDonald WM, Goldstein FC. Affective Correlates of Psychosis in Parkinson's Disease. Mov Disord Clin Pract. 2017 Mar-Apr;4(2):225-230. doi: 10.1002/mdc3.12381. Epub 2016 Jun 16. PMID: 28944257; PMCID: PMC5608273.
Copy Download .nbib Format: NLM
Reversing factor Xa inhibitors - clinical utility of andexanet alfa.

Journal of blood medicine

Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG.
PMID: 28979172
J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017.

Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent...

Cite
Kaatz S, Bhansali H, Gibbs J, et al. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017;8:141-149doi: 10.2147/JBM.S121550.
Kaatz, S., Bhansali, H., Gibbs, J., Lavender, R., Mahan, C. E., & Paje, D. G. (2017). Reversing factor Xa inhibitors - clinical utility of andexanet alfa. Journal of blood medicine, 8141-149. https://doi.org/10.2147/JBM.S121550
Kaatz, Scott, et al. "Reversing factor Xa inhibitors - clinical utility of andexanet alfa." Journal of blood medicine vol. 8 (2017): 141-149. doi: https://doi.org/10.2147/JBM.S121550
Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017. PMID: 28979172; PMCID: PMC5602457.
Copy Download .nbib Format: NLM
Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke.

Journal of stroke

Jung KH, Yu KH, Kim YD, Park JM, Hong KS, Rha JH, Kwon SU, Bae HJ, Heo JH, Lee BC, Yoon BW.
PMID: 26060808
J Stroke. 2015 May;17(2):210-5. doi: 10.5853/jos.2015.17.2.210. Epub 2015 May 29.

Cardioembolic stroke related to nonvalvular atrial fibrillation is associated with a high recurrence rate and high mortality and morbidity. In this population, therefore, optimal anticoagulant therapy is required to prevent the occurrence of second stroke. Oral anticoagulant, warfarin has...

Cite
Jung KH, Yu KH, Kim YD, et al. Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. J Stroke. 2015;17(2):210-5doi: 10.5853/jos.2015.17.2.210.
Jung, K. H., Yu, K. H., Kim, Y. D., Park, J. M., Hong, K. S., Rha, J. H., Kwon, S. U., Bae, H. J., Heo, J. H., Lee, B. C., & Yoon, B. W. (2015). Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. Journal of stroke, 17(2), 210-5. https://doi.org/10.5853/jos.2015.17.2.210
Jung, Keun-Hwa, et al. "Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke." Journal of stroke vol. 17,2 (2015): 210-5. doi: https://doi.org/10.5853/jos.2015.17.2.210
Jung KH, Yu KH, Kim YD, Park JM, Hong KS, Rha JH, Kwon SU, Bae HJ, Heo JH, Lee BC, Yoon BW. Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. J Stroke. 2015 May;17(2):210-5. doi: 10.5853/jos.2015.17.2.210. Epub 2015 May 29. PMID: 26060808; PMCID: PMC4460340.
Copy Download .nbib Format: NLM
Global assays and the management of oral anticoagulation.

Thrombosis journal

Brinkman HJ.
PMID: 25762867
Thromb J. 2015 Feb 10;13:9. doi: 10.1186/s12959-015-0037-1. eCollection 2015.

Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the principle of the test and the type of...

Cite
Brinkman HJ. Global assays and the management of oral anticoagulation. Thromb J. 2015;13:9doi: 10.1186/s12959-015-0037-1.
Brinkman, H. J. (2015). Global assays and the management of oral anticoagulation. Thrombosis journal, 139. https://doi.org/10.1186/s12959-015-0037-1
Brinkman, Herm Jan M. "Global assays and the management of oral anticoagulation." Thrombosis journal vol. 13 (2015): 9. doi: https://doi.org/10.1186/s12959-015-0037-1
Brinkman HJ. Global assays and the management of oral anticoagulation. Thromb J. 2015 Feb 10;13:9. doi: 10.1186/s12959-015-0037-1. eCollection 2015. PMID: 25762867; PMCID: PMC4355453.
Copy Download .nbib Format: NLM
Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series.

Clinical kidney journal

Russcher M, Josephus Jitta N, Kraaijenhagen RJ, Fijnheer R, Pasker-de Jong PC, Gaillard CA.
PMID: 26064511
Clin Kidney J. 2013 Oct;6(5):473-7. doi: 10.1093/ckj/sft083. Epub 2013 Sep 05.

BACKGROUND: Low-molecular-weight heparins (LMWHs) are frequently used to treat arterial and venous thrombo-embolic events. LMWHs accumulate with renal failure, but only limited clinical data regarding appropriate dosage adjustments are available. Nevertheless, LMWHs are routinely used in these patients worldwide....

Cite
Russcher M, Josephus Jitta N, Kraaijenhagen RJ, et al. Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series. Clin Kidney J. 2013;6(5):473-7doi: 10.1093/ckj/sft083.
Russcher, M., Josephus Jitta, N., Kraaijenhagen, R. J., Fijnheer, R., Pasker-de Jong, P. C., & Gaillard, C. A. (2013). Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series. Clinical kidney journal, 6(5), 473-7. https://doi.org/10.1093/ckj/sft083
Russcher, Marije, et al. "Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series." Clinical kidney journal vol. 6,5 (2013): 473-7. doi: https://doi.org/10.1093/ckj/sft083
Russcher M, Josephus Jitta N, Kraaijenhagen RJ, Fijnheer R, Pasker-de Jong PC, Gaillard CA. Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series. Clin Kidney J. 2013 Oct;6(5):473-7. doi: 10.1093/ckj/sft083. Epub 2013 Sep 05. PMID: 26064511; PMCID: PMC4438398.
Copy Download .nbib Format: NLM
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.

Therapeutics and clinical risk management

Mekaj YH, Mekaj AY, Duci SB, Miftari EI.
PMID: 26150723
Ther Clin Risk Manag. 2015 Jun 24;11:967-77. doi: 10.2147/TCRM.S84210. eCollection 2015.

Despite the discovery and application of many parenteral (unfractionated and low-molecular-weight heparins) and oral anticoagulant vitamin K antagonist (VKA) drugs, the prevention and treatment of venous and arterial thrombotic phenomena remain major medical challenges. Furthermore, VKAs are the only...

Cite
Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967-77doi: 10.2147/TCRM.S84210.
Mekaj, Y. H., Mekaj, A. Y., Duci, S. B., & Miftari, E. I. (2015). New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeutics and clinical risk management, 11967-77. https://doi.org/10.2147/TCRM.S84210
Mekaj, Ymer H, et al. "New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events." Therapeutics and clinical risk management vol. 11 (2015): 967-77. doi: https://doi.org/10.2147/TCRM.S84210
Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015 Jun 24;11:967-77. doi: 10.2147/TCRM.S84210. eCollection 2015. PMID: 26150723; PMCID: PMC4485791.
Copy Download .nbib Format: NLM
ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation.

Global cardiology science & practice

ElMaghawry M.
PMID: 26779514
Glob Cardiol Sci Pract. 2015 Oct 02;2015(3):35. doi: 10.5339/gcsp.2015.35. eCollection 2015.

In a recent article in the Journal, we have reviewed the adverse cardiovascular outcomes observed with digoxin use in the PALLAS study.(1) The PALLAS study was designed to determine if dronedarone would reduce major vascular events in patients with...

Cite
ElMaghawry M. ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation. Glob Cardiol Sci Pract. 2015;2015(3):35doi: 10.5339/gcsp.2015.35.
ElMaghawry, M. (2015). ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation. Global cardiology science & practice, 2015(3), 35. https://doi.org/10.5339/gcsp.2015.35
ElMaghawry, Mohamed. "ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation." Global cardiology science & practice vol. 2015,3 (2015): 35. doi: https://doi.org/10.5339/gcsp.2015.35
ElMaghawry M. ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation. Glob Cardiol Sci Pract. 2015 Oct 02;2015(3):35. doi: 10.5339/gcsp.2015.35. eCollection 2015. PMID: 26779514; PMCID: PMC4633576.
Copy Download .nbib Format: NLM
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].

Kardiologiia

Shevelev VI, Kanorsky SG.
PMID: 28294796
Kardiologiia. 2015 Oct;55(10):58-63. doi: 10.18565/cardio.2015.10.58-63.

We compared efficacy and safety of warfarin with those of direct thrombin inhibitor dabigatran, factor Xa inhibitors rivaroxaban and apixaban used for stroke prevention in 280 patients aged 65-80 years with non-valvular atrial fibrillation. Treatment for two years with...

Cite
Shevelev VI, Kanorsky SG. [Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]. Kardiologiia. 2015;55(10):58-63doi: 10.18565/cardio.2015.10.58-63.
Shevelev, V. I., & Kanorsky, S. G. (2015). [Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]. Kardiologiia, 55(10), 58-63. https://doi.org/10.18565/cardio.2015.10.58-63
Shevelev, V I, and Kanorsky, S G. "[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]." Kardiologiia vol. 55,10 (2015): 58-63. doi: https://doi.org/10.18565/cardio.2015.10.58-63
Shevelev VI, Kanorsky SG. [Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]. Kardiologiia. 2015 Oct;55(10):58-63. doi: 10.18565/cardio.2015.10.58-63. Russian. PMID: 28294796.
Copy Download .nbib Format: NLM
PO-23 - Expression of heparanase in cancer as biomarker of malignancies: overexpression in an aggressive, poor survival gastric cancer "gastric signet ring cell carcinoma" compared with that of other gastric cancers.

Thrombosis research

Fourgeaud C, Derieux S, Mirshahi S, Besbes S, Chidiac J, Mahé I, Contant G, Pocard M, Soria J, Mirshahi M.
PMID: 27161709
Thromb Res. 2016 Apr;140:S184-5. doi: 10.1016/S0049-3848(16)30156-6. Epub 2016 Apr 08.

INTRODUCTION: Gastric signet ring cell carcinoma (GSRC) is a distinct entity among of other gastric cancer. With unknown etiopathology, their incidence is increasing and it presents a low sensitivity to chemotherapy.AIM: Here, we studied the expression of the heparanase...

Cite
Fourgeaud C, Derieux S, Mirshahi S, et al. PO-23 - Expression of heparanase in cancer as biomarker of malignancies: overexpression in an aggressive, poor survival gastric cancer "gastric signet ring cell carcinoma" compared with that of other gastric cancers. Thromb Res. 2016;140:S184-5doi: 10.1016/S0049-3848(16)30156-6.
Fourgeaud, C., Derieux, S., Mirshahi, S., Besbes, S., Chidiac, J., Mahé, I., Contant, G., Pocard, M., Soria, J., & Mirshahi, M. (2016). PO-23 - Expression of heparanase in cancer as biomarker of malignancies: overexpression in an aggressive, poor survival gastric cancer "gastric signet ring cell carcinoma" compared with that of other gastric cancers. Thrombosis research, 140S184-5. https://doi.org/10.1016/S0049-3848(16)30156-6
Fourgeaud, C, et al. "PO-23 - Expression of heparanase in cancer as biomarker of malignancies: overexpression in an aggressive, poor survival gastric cancer "gastric signet ring cell carcinoma" compared with that of other gastric cancers." Thrombosis research vol. 140 (2016): S184-5. doi: https://doi.org/10.1016/S0049-3848(16)30156-6
Fourgeaud C, Derieux S, Mirshahi S, Besbes S, Chidiac J, Mahé I, Contant G, Pocard M, Soria J, Mirshahi M. PO-23 - Expression of heparanase in cancer as biomarker of malignancies: overexpression in an aggressive, poor survival gastric cancer "gastric signet ring cell carcinoma" compared with that of other gastric cancers. Thromb Res. 2016 Apr;140:S184-5. doi: 10.1016/S0049-3848(16)30156-6. Epub 2016 Apr 08. PMID: 27161709.
Copy Download .nbib Format: NLM
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects.

Clinical pharmacology in drug development

Matsushima N, Lee F, Sato T, Weiss D, Mendell J.
PMID: 27121940
Clin Pharmacol Drug Dev. 2013 Oct;2(4):358-66. doi: 10.1002/cpdd.53. Epub 2013 Sep 09.

BACKGROUND: Edoxaban is an oral, once-daily, direct factor Xa inhibitor under investigation for stroke prevention in patients with atrial fibrillation and for treatment and secondary prevention of venous thromboembolism. This study evaluated edoxaban absolute bioavailability and effects of the...

Cite
Matsushima N, Lee F, Sato T, et al. Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clin Pharmacol Drug Dev. 2013;2(4):358-66doi: 10.1002/cpdd.53.
Matsushima, N., Lee, F., Sato, T., Weiss, D., & Mendell, J. (2013). Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clinical pharmacology in drug development, 2(4), 358-66. https://doi.org/10.1002/cpdd.53
Matsushima, Nobuko, et al. "Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects." Clinical pharmacology in drug development vol. 2,4 (2013): 358-66. doi: https://doi.org/10.1002/cpdd.53
Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clin Pharmacol Drug Dev. 2013 Oct;2(4):358-66. doi: 10.1002/cpdd.53. Epub 2013 Sep 09. PMID: 27121940.
Copy Download .nbib Format: NLM
Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.

Research and practice in thrombosis and haemostasis

Deguchi H, Elias DJ, Griffin JH.
PMID: 29082360
Res Pract Thromb Haemost. 2017 Jul;1(1):93-102. doi: 10.1002/rth2.12017. Epub 2017 Jun 20.

Different minor abundance plasma lipids significantly influence thrombin generation in vitro and significant differences in such lipids are linked to risk for venous thrombosis. Some plasma sphingolipids including glucosylceramide, lyso-sulfatide and sphingosine have anticoagulant properties whereas, conversely, some plasma...

Cite
Deguchi H, Elias DJ, Griffin JH. Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. Res Pract Thromb Haemost. 2017;1(1):93-102doi: 10.1002/rth2.12017.
Deguchi, H., Elias, D. J., & Griffin, J. H. (2017). Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. Research and practice in thrombosis and haemostasis, 1(1), 93-102. https://doi.org/10.1002/rth2.12017
Deguchi, Hiroshi, et al. "Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk." Research and practice in thrombosis and haemostasis vol. 1,1 (2017): 93-102. doi: https://doi.org/10.1002/rth2.12017
Deguchi H, Elias DJ, Griffin JH. Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. Res Pract Thromb Haemost. 2017 Jul;1(1):93-102. doi: 10.1002/rth2.12017. Epub 2017 Jun 20. PMID: 29082360; PMCID: PMC5658053.
Copy Download .nbib Format: NLM
Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices.

Cardiology and therapy

Saraiva JFK.
PMID: 29488150
Cardiol Ther. 2018 Jun;7(1):15-24. doi: 10.1007/s40119-018-0106-1. Epub 2018 Feb 27.

Atrial fibrillation (AF) is an established risk factor for a first or recurrent stroke. Despite proven efficacy in preventing stroke in patients with AF, warfarin is underused, partly due to safety concerns. Recent randomized trials have shown that non-vitamin...

Cite
Saraiva JFK. Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiol Ther. 2018;7(1):15-24doi: 10.1007/s40119-018-0106-1.
Saraiva, J. F. K. (2018). Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiology and therapy, 7(1), 15-24. https://doi.org/10.1007/s40119-018-0106-1
Saraiva, José Francisco Kerr. "Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices." Cardiology and therapy vol. 7,1 (2018): 15-24. doi: https://doi.org/10.1007/s40119-018-0106-1
Saraiva JFK. Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiol Ther. 2018 Jun;7(1):15-24. doi: 10.1007/s40119-018-0106-1. Epub 2018 Feb 27. PMID: 29488150; PMCID: PMC5986671.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 841 entries